Drug intelligence / Profile preview

BDNF-EXO

Development stage
Unknown
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

**BDNF-EXO** refers to **exosomes loaded with brain-derived neurotrophic factor (BDNF)**, typically derived from human umbilical cord mesenchymal stem cells or neural stem cells, and engineered to deliver BDNF directly to target tissues. BDNF is a neurotrophic protein crucial for the survival and function of neurons, binding primarily to the TrkB receptor (tropomyosin receptor kinase B), activating signaling pathways involved in neuronal survival, differentiation, and plasticity in neurodegenerative and neuropsychiatric disorders. BDNF-EXO leverages exosomes as a delivery vehicle to cross the blood-brain barrier, enabling efficient CNS delivery. Preclinical studies in Parkinson's disease models show that BDNF-EXO suppresses apoptosis and ferroptosis, stabilizes neuronal cytoskeleton, promotes antioxidant defense via Nrf2 signaling, and generally improves neurological outcomes. Similar approaches, with BDNF-engineered exosomes, have been employed in models of major depressive disorder and ischemic stroke, showing neuroprotective and anti-inflammatory actions. BDNF-EXO is an emerging therapy for CNS diseases resistant to conventional drug delivery due to the blood-brain barrier.

02

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)

Beyond the preview

Go deeper on BDNF-EXO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDNF-EXO.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call